BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Rides On Bunavail

782

Dallas, Texas 01/23/2014 (FINANCIALSTRENDS) – BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has been moving Bunavil to capture the $1.5 billion Suoxone market segment. The company anticipates acquisition of $250million in the opioid dependent treatment.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) had moved Bunavil through the New Drug Application, which will be completed by June 2014. The company expects to see the sale of this drug to be in the region of $250 million.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) along with EndoPharmaceuticals, has movedinto the Phase 3 development of its BEMA product Buprenorphine.  As is typical of BioDelviery, all products are developed into unique applications by tying up with third parties, such as EndoPharmaceuticals. The earlier interim results for the drug have shown that there was requirement for adjustments to be done to the sample sizes during the opioid naïve study phase.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) holds a market cap of $243.88 million and volume of 660, 703. The stock also holds 52 week high of $6.64 and 52 week low of $3.52. The EPS for the company is -1.25. The US based company operates in the Bio technology sector and offers specialized pharmaceutical products, which are delivery technologies. These utilize licensed as well as owned proprietary drug, delivery technologies which commercialize as well as formulate already available therapies.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has since included new expertise on its management scene with the inclusion of a new VP sales and managed markets- David Acheson, in the first week of December. The company has also commenced the Phase 3 trial of Clonidine Topical Gel which is in PDN to move into first quarter of 2014. This follows a meeting with the Food and Drug Administration, which proved to be positive for the company product.

BioDelivery Sciences is expected to see massive sales of Bunavil in the next couple of quarters and has since offered positive guidance based on the same.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.